HLB Pharmaceutical Starts Construction on New S55 Billion Hyangnam Plant to Expand Production
HLB Pharmaceutical began building a new plant in Hwaseong with annual capacity of 700 million tablets, aiming to increase output and support growth by 2029.
HLB Pharmaceutical broke ground on a new manufacturing facility in Hwaseong, Gyeonggi Province, with a planned investment of 55 billion won ($41.4 million) to nearly triple its production capacity and support growth towards 1 trillion won in annual sales by 2036.
New Plant to Increase Tablet Production Capacity
The existing Namyangju plant produces approximately 250 million tablets annually, which CEO Park Jae-hyung indicated was insufficient to meet rising demand, resulting in significant reliance on external contract manufacturing.
The new Hyangnam plant is expected to have an annual output capacity of around 700 million tablets. The facility will occupy 11,931 square meters within a 31,244-square-meter site and will include one basement level and three floors above ground. Construction is scheduled for completion by late 2027, with full operational approval targeted by the end of the same year.
Operational and Strategic Implications
Following Good Manufacturing Practice certification, HLB plans to transition production from Namyangju and begin full-scale operations at Hyangnam in 2029. The company aims to reduce dependence on external manufacturers, improve cost efficiencies, and support new product launches as well as expansion of its contract manufacturing organisation (CMO) business.
HLB Pharmaceutical reported sales of 205.6 billion won in 2022 and recorded a first half 2023 revenue of 127.9 billion won, reflecting positive business momentum. The Hyangnam facility is expected to become a key manufacturing hub within the HLB Group, enabling production of new drugs and allowing potential further expansion aligned with adjacent land development plans.
The company outlined a 10-year strategy to become one of South Korea’s top 10 pharmaceutical firms by 2036, reaching 1 trillion won in annual revenue. Priorities include strengthening prescription drug offerings, developing enhanced versions of existing medicines, and pursuing strategic mergers and acquisitions, particularly in oncology, urology, and rare diseases.
HLB Group Chairman Jin Yang-gon noted the company’s ambition to evolve beyond cancer drug development into a stable supplier of quality medicines at the global level, emphasising that the Hyangnam plant would embody this mission through high-quality production capabilities.
Key milestones to watch include completion of construction and regulatory certification by the end of 2027, and the commencement of full production in 2029 as the company progresses with its longer-term expansion objectives.

